ASCO 2019 ANNUAL MEETING

ASCO 2019 ANNUAL MEETING

INTERVIEW WITH EVAN YU
Management of mCRPC using Sipuleucel-T

VIEW ALL mCRPC VIDEOS

ASCO 2019 ANNUAL MEETING

ASCO 2019 ANNUAL MEETING

INTERVIEW WITH JACOB BERCHUCK & MARY-ELLEN TAPLIN
Genetic Risk in Prostate Cancer

VIEW ALL PROSTATE CANCER VIDEOS

ASCO 2019 ANNUAL MEETING

ASCO 2019 ANNUAL MEETING

INTERVIEW WITH KARIM FIZAZI
ARAMIS Trial in Prostate Cancer: Impact of Darolutamide on Pain and Quality of Life

VIEW ALL nmCRPC VIDEOS

EAU 2019 ANNUAL MEETING

EAU 2019 ANNUAL MEETING

INTERVIEW WITH THOMAS POWLES
Immunotherapy in the Peri-Operative Setting for Bladder Cancer

VIEW ALL BLADDER CANCER VIDEOS

Videos
State-of-the-industry video lectures by leading urology experts
Featured Videos

EAU 2014 - The added value of intracorporeal urinary diversion after robotic radical cystectomy: A propensity matched comparative study - Session Highlights

STOCKHOLM, SWEDEN (UroToday.com) - This abstract was presented by Dr. Idir Ouzaid from Glickman Urological and Kidney Institute, Cleveland. The objective of this presentation was to compare perioperative and short-term outcomes of patients undergoing extracorporeal robotic assisted laparoscopic radical cystectomy (ecRARC) and intracorporeal robotic assisted laparoscopic radical cystectomy (icRARC) in a propensity matched fashion. Outcomes on 125 patients who underwent RARC and urinary diversion (UD) were presented. Of these, 45 and 80 patients underwent icRARC and ECRARC, respectively. Propensity-score matching was performed in a 1:1 ratio using disease characteristics (TURBT pathology and neoadjuvant chemotherapy), baseline demographics (age, gender, BMI, Charlson comorbidity score, history of smoking, and history of abdominal surgeries), and type of ileal UD (conduit and neobladders). Matched patients were compared with respect to their operative time, estimated blood loss (EBL), length of stay (LOS), time to oral diet, and 90-days complications. Ninety-days readmission and secondary procedure rates were also compared between the two cohorts.

eauThe group reported that patients who received icRARC had significantly lower EBL compared to the ecRARC group (p = 0.005) and the rate of transfusion was lower (22% vs. 42%, p = 0.07). Operative time, LOS, time to oral intake, as well as complication rates were reported similarly between the two cohorts.

In summary, robotic assisted laparoscopic radical cystectomy is gaining in popularity as an alternative to the open approach. Authors demonstrated that icRARC has the potential benefit of decreased estimated blood loss over ecRARC without additional morbidity and surgery time. Reported results should be further validated by other centers and larger cohorts.

Presented by Idir Ouzaid at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

Cleveland Clinic, Glickman Urological and Kidney Institute, Cleveland USA

Written by Reza Mehrazin, MD, medical writer for UroToday.com

 

Conference Coverage
 
Recent data from conferences worldwide
Journals
Publications focusing on urologic cancer treatments through original manuscripts
Everyday Urology Volume 4 Issue 1

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe